Screening for those at high risk for T2DM does not reduce mortality within 10 years, study finds
Screening patients who are at high risk for diabetes does not reduce their all-cause, cardiovascular, or diabetes-related mortality within 10 years, according to a study published October 4 in The Lancet.
During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.